GPT Antibody (B-1): sc-271370
- GPT Antibody (B-1) is a mouse monoclonal IgG3 κ provided at 200 µg/ml
- specific for an epitope mapping between amino acids 2-33 at the N-terminus of GPT of mouse origin
- recommended for detection of GPT of mouse origin by WB, IP, IF and ELISA
- m-IgG3 BP-HRP is the preferred secondary detection reagent for GPT Antibody (B-1) for WB applications. This reagent is now offered in a bundle with GPT Antibody (B-1) (see ordering information below).
QUICK LINKS
GPT Antibody (B-1) is a mouse monoclonal IgG3 antibody that detects glutamate pyruvate transaminase (GPT) in mouse samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-GPT antibody (B-1) plays a crucial role in amino acid metabolism by catalyzing the reversible transamination between alanine and 2-oxoglutarate, resulting in the formation of pyruvate and glutamate. This enzymatic activity is vital for maintaining the balance of glucose and amino acids in the body, which is essential for energy production and metabolic homeostasis. GPT monoclonal antibody (B-1) is predominantly located in the liver, kidney, and heart, where GPT contributes to the regulation of metabolic pathways. Notably, GPT (B-1) antibody is often utilized as a biomarker for liver integrity and hepatocellular damage in clinical diagnostics, making GPT an important target for research and therapeutic applications. Anti-GPT antibody (B-1) provides reliable detection and quantification of GPT, facilitating studies on GPT′s role in metabolic disorders and liver function.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
GPT Antibody (B-1) References:
- Demonstration of antibody for glutamic pyruvic transaminase (GPT) in chronic hepatic disorders. | Kajita, Y., et al. 1978. Clin Chim Acta. 89: 485-92. PMID: 101321
- The mechanism of release of hepatic enzymes in various liver diseases. II. Altered activity ratios of GOT to GPT in serum and liver of patients with liver diseases. | Miyake, S. 1979. Acta Med Okayama. 33: 343-58. PMID: 160182
- In vivo genotoxicity of 1-methylnaphthalene from comprehensive toxicity studies with B6C3F1 gpt delta mice. | Jin, M., et al. 2012. J Toxicol Sci. 37: 711-21. PMID: 22863852
- Gene dosage evidence for the regional assignment of GPT (glutamate-pyruvate transaminase; E.C. 2.6.1.2) locus to 8q24.2----8qter. | Rocha, J., et al. 1988. Hum Genet. 80: 299-300. PMID: 3192219
- Agarose gel electrophoresis of human erythrocyte glutamic-pyruvic transaminase (GPT EC 2.6.1.2). | Bär, W. and Biedermann, V. 1987. Forensic Sci Int. 33: 69-73. PMID: 3817677
- GOT, GPT and LDH levels and blood viscosity factors after recent myocardial infarction. Effect of ABO blood groups. | Dintenfass, L. and Forbes, CD. 1974. Haematologia (Budap). 8: 523-33. PMID: 4461436
- Increase in serum-GPT and serum-LDH after administration of morphine to patients suffering from bile-duct dyskinesia. | Laursen, T. and Schmidt, A. 1966. Scand J Clin Lab Invest Suppl. 18: 175-7. PMID: 5958517
- Chromosomal location of soluble glutamic-pyruvic transaminase-1 (Gpt-1) in the mouse. | Eicher, EM. and Womack, JE. 1977. Biochem Genet. 15: 1-8. PMID: 849243
- Serum creatinine concentrations, S-GOT and S-GPT activities and lead exposure. | Tola, S. and Nordman, CH. 1977. Int Arch Occup Environ Health. 39: 37-44. PMID: 852897
- Development of a novel CHL/IU cell line with an incorporated gpt shuttle vector for concurrent analysis of gene mutations and chromosome aberrations. | Yamada, T., et al. 1997. Mutat Res. 393: 295-306. PMID: 9393622
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GPT Antibody (B-1) | sc-271370 | 200 µg/ml | $316.00 | |||
GPT Antibody (B-1): m-IgG3 BP-HRP Bundle | sc-550405 | 200 µg Ab; 40 µg BP | $354.00 | |||
GPT (B-1) Neutralizing Peptide | sc-271370 P | 100 µg/0.5 ml | $68.00 |